Search results
Showing 46 to 60 of 187 results for prostate cancer
Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. This involves pushing the rectum slightly away from the prostate by inserting a balloon or injecting a gel (spacer) between them.
View recommendations for HTG659Show all sections
NICE has developed a medtech innovation briefing (MIB) on Paige Prostate for prostate cancer .
Evidence-based recommendations on high dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer. This involves using radiotherapy to treat the cancer from both outside of the body and from within the affected area.
View recommendations for HTG113Show all sections
Sections for HTG113
In development Reference number: GID-MT526 Expected publication date: TBC
trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)
NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .
NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .
NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised
Axumin for functional imaging of prostate cancer recurrence (MIB172)
NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Prolaris gene expression assay for assessing long-term risk of prostate cancer progression (MIB65)
NICE has developed a medtech innovation briefing (MIB) on the Prolaris gene expression assay for assessing long-term risk of prostate cancer progression
This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.
Transperineal template biopsy and mapping of the prostate (HTG237)
Evidence-based recommendations on transperineal template biopsy of the prostate. This involves inserting many fine needles though the skin between the scrotum and the anus in order to obtain tissue samples from the prostate for testing.
View recommendations for HTG237Show all sections
Sections for HTG237
Evidence-based recommendations on laparoscopic radical prostatectomy. This involves removing the prostate gland and some surrounding tissue using specialised instruments through small cuts in the abdomen (keyhole surgery).
View recommendations for HTG125Show all sections
Sections for HTG125
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
NG12/05 Question Prostate-specific antigen testing: What is the diagnostic accuracy of using age-adjusted and fixed...